This is an aggregated industry headline. Read the full story at Drug Channels →
Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo
Spring is here in always-sunny Philadelphia. The vernal equinox has brought us an unexpected bounty of noteworthy news: Cigna’s clever vertical integration move Merck cuts drug prices—and Medicaid and 340B pay more Walgreens’ big pharmacy technology play How plans profit—and patients lose—from highl
By Drug Channels
· Mar 31, 2026
· via Drug Channels
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The FDA has converted its accelerated approval for Novartis' Fabhalta into a full blessing to treat patients w…
The WeekFierceBiotech ↗
Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Thera…
The WeekBriefing
The European Commission cleared Novo Nordisk’s oral Wegovy, giving the company a head start over Eli Lilly’s s…